Literature DB >> 21349409

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

Ben Lawrence1, Bjorn I Gustafsson, Anthony Chan, Bernhard Svejda, Mark Kidd, Irvin M Modlin.   

Abstract

In this article, updated analyses of the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) registry (1973-2007) are presented and compared with epidemiologic GEP-NET data from Europe and Asia. Several studies have demonstrated a steadily increasing incidence of GEP-NETs, and this escalation is still ongoing (SEER data 2004-2007). The common primary GEP-NET sites exhibit unique epidemiologic profiles with distinct patterns of incidence, age at diagnosis, stage, and survival. Overall, GEP-NET survival has improved over the past 3 decades, although the outcome for poorly differentiated tumors remains dismal.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21349409     DOI: 10.1016/j.ecl.2010.12.005

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  279 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

2.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 3.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 4.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

5.  Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.

Authors:  Safia Salaria; Anna Means; Frank Revetta; Kamran Idrees; Eric Liu; Chanjuan Shi
Journal:  Am J Clin Pathol       Date:  2015-10       Impact factor: 2.493

Review 6.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.

Authors:  Sarah Wulfert; Clemens Kratochwil; Peter L Choyke; Ali Afshar-Oromieh; Walter Mier; Hans-Ulrich Kauczor; Jens-Peter Schenk; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

Review 8.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

9.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

10.  Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.

Authors:  Michelle Kang Kim; Richard R P Warner; Sasan Roayaie; Noam Harpaz; Stephen C Ward; Steven Itzkowitz; Juan P Wisnivesky
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.